Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.

Tony Antoniou, Alice L Tseng, Rolf P G van Heeswijk, Scott E Walker, Pierre Giguere, Elizabeth J Phillips

Journal: Therapeutic drug monitoring 2006;27(6):779-81

PMID: 16306854

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Six HIV-positive antiretroviral experienced patients initiating therapy with a regimen including lopinavir/ritonavir (400/100 mg twice per day) and indinavir (800 mg twice per day) underwent steady-state pharmacokinetic analysis. The AUC0-12 h of indinavir when combined with lopinavir/ritonavir was comparable with previously published data on indinavir/ritonavir 800/100 mg twice per day in HIV-infected individuals. However, lopinavir AUC0-12 h, Cmax, and C12 h were lower than previously reported in the absence of indinavir. The regimen was well tolerated, although 2 patients developed grade 3 hypertriglyceridemia. No patient discontinued the regimen because of indinavir-related urologic or retinoid-type adverse effects. Further study of the regimen with larger cohorts of patients is necessary.

Address: St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. [email protected]

DOI: 10.1097/01.ftd.0000177665.34845.fa

Link outs

Free resources

Medical:

https://medlineplus.gov/hivinwomen.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Area Under Curve, Chromatography, High Pressure Liquid, Drug Therapy, Combination, Female, HIV Infections, HIV Protease Inhibitors, Humans, Hypertriglyceridemia, Indinavir, Lopinavir, Male, Metabolic Clearance Rate, Pyrimidinones